Searched for
INDIAN DRUG FACILITIES
These large-, mid- and small-cap stocks have upside potential of up to 31% in 1 year, according to analystsIn the last two years, the world has learnt that you can never quite predict what US President Trump will do next. Tomorrow, to pull attent...- FDA flags persistent data-integrity lapses, insanitary conditions at Indian drug facilitiesThe US FDA continues to identify serious data integrity issues in Indian pharmaceutical manufacturing facilities. During inspections, inspe...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and upside potential of up to 28%, according to analystsGlobal markets on Wednesday celebrated the outcome of the US mid-term election as well as a sharp drop in oil prices. Oil prices, which at ...
- With most drug candidates failing in humans, India’s draft rules bet on the wrong science in animal lab testingRecent draft rules in India threaten advancements in non-animal testing for drug development and safety. The new regulations may prioritize...
- Vantara hosts EARAZA conference, puts data and technology at the heart of wildlife conservationThe four-day EARAZA Annual Conference 2026 at Anant Ambani’s Vantara in Jamnagar brought together 98 institutions from 30 countries. Vantar...
- Sun Pharma ordered to halt eye drug production at Assam plant over quality lapses: ReportIndian regulators have ordered Sun Pharmaceutical Industries to stop manufacturing ophthalmic products at the Assam facility. This decision...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsWhen a market is as jittery as it is right now, poor numbers are treated harshly. A new-age company in the business of buying and selling u...
- Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini PiramalIn a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The ...
- Sugar stocks: Short-term pain is real; has the long-term case broken? 7 stocks from the sugar-ethanol ecosystemThough this year's ethanol tender leaves sugar out, the long-term blending roadmap still points to rising ethanol use. The move is aimed at...
- Stocks in news: Infosys, Kotak Mahindra Bank, YES Bank, Raymond, BPCL, Coforge and Senco GoldIndian equity markets have faced a decline for four consecutive sessions, with the Nifty falling significantly. Various factors, including ...
- From nasal delivery to sterile injectables: Biodeal Pharmaceuticals’ expansion plansBiodeal Pharmaceuticals is set to broaden its horizons with a state-of-the-art sterile injectables plant in Himachal Pradesh. This venture ...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsThe last few weeks have made one thing clear. Oil prices, US bond yields, corporate earnings, and the state of the world – all point the sa...
- Don't stunt the stent, med devices sectorThree coronary stent models from Meril Life Sciences were withdrawn from the Sri Lankan market due to performance issues. The National Medi...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsThe next few weeks are critical, and one should not be in a hurry to make market-related decisions. Better to be cautious – to wait and wat...
- RBI to continue efforts to curb rupee volatility; external factors driving currency fall: FMFinance Minister Nirmala Sitharaman mentioned the Reserve Bank of India’s ongoing efforts to stabilize the rupee's value. She noted that th...
- ET Startup Awards 2026: Deeptech wants government to step up as the first customerAt the discussion, titled ‘Building the Hard Stuff in India’, moderated by Accel partner Prashanth Prakash, founders from the space, semico...
- Healthcare paradox: More access, but who pays?Scaling too fast is irrelevant. The real problem is that India still confuses more hospitals, more doctors and more medicines with better h...
- CPHI Milan: Beyond generics, how Indian pharma is rewriting its global playbookAt CPHI Milan, Indian pharma players are looking beyond traditional exports, using partnerships, licensing, CDMO, and differentiated produc...
- These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystsIn the short term, be ready for volatility, and do not mistake the passing of one big event for an all-clear. In the long term, give up try...
- When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends ...
Load More
